Review of prognostic factors of anti-vascular endothelial growth factor therapy on choroidal neovascularization secondary to pathological myopia

Abstract

For choroidal neovascularization (CNV) secondary to pathological myopia, intravitreal injection of anti-VEGF has been widely used in clinic and achieved good outcome. However, due to the differences in the demographic characteristics, stages of disease progression and treatment procedure of CNV, the prognosis of the disease is variable. Complete ellipsoid band, smaller baseline choroidal neovascularization and better baseline vision are important predictors of good outcome of anti-vascular endothelial growth factor treatment. Chorioretinal atrophy or complications related to pathologic myopia indicate a poor prognosis. The influence of age, race, previous photodynamic therapy and early treatment on the prognosis of treatment need to be further studied. Key words: Myopia, degenerative/complications; Choroidal neovascularization/drug therapy; Angiogenesis inhibitors/therapeutic applications; Antibodies, monoclonal/therapeutic applications; Review